Target intelligence / Profile preview

Reticulon-4 (Nogo-A) (Nogo-A)

Target
Nogo-A
Molecular classification
Other (Reticulon family protein), Membrane-associated protein, Inhibitor (neurite outgrowth inhibitor)
01

Overview

Reticulon-4, also known as Nogo-A, is a membrane-associated protein encoded by the RTN4 gene, primarily expressed in the central nervous system. It is the most well-characterized inhibitor of neurite outgrowth, limiting neuronal regeneration and plasticity after injury by interacting with the Nogo receptor (NgR1) complex. Nogo-A contains multiple inhibitory domains, including amino-Nogo and Nogo-66, which restrict axonal growth and contribute to the failure of CNS neurons to regenerate after injury. Besides its role in axonal inhibition, Reticulon-4/Nogo-A participates in the shaping of endoplasmic reticulum membranes and regulates protein folding by interacting with ER-resident proteins such as protein disulfide isomerase. Pathophysiologically, Nogo-A is implicated in neurodegenerative diseases, spinal cord injury, multiple sclerosis, and stroke, making it a significant target for therapeutics aimed at promoting neural regeneration and recovery in the CNS[1][2][3][4][5][6][7].

Other names
Neurite outgrowth inhibitorRTN4NogoNogo proteinReticulon-4A
02

Mechanism of action

Inhibition of Nogo-A (for example, by anti-Nogo-A antibodies) neutralizes its axon growth-inhibiting effects, potentially promoting neural regeneration and functional recovery after CNS injury[1][3].

03

Biological functions

Regulation of neurite outgrowthNegative regulation of neuronal growthInhibition of neural regenerationRestriction of CNS plasticityEndoplasmic reticulum membrane shapingRestriction of blood vessel densityProtein folding regulation in ER
04

Disease associations

Neurodegenerative diseaseSpinal cord injuryMultiple sclerosisAmyotrophic lateral sclerosis (ALS)Ischemic strokeOther CNS injuries
05

Safety considerations

Potential risk of aberrant neural sprouting, uncontrolled synaptic plasticity, and possibly unintended effects on vascular stability or neural circuit integrity due to removal of growth inhibition[1][3]
06

Interacting drugs

No approved drugs directly target Reticulon-4/Nogo-A, but experimental anti-Nogo-A antibodies are being investigated for CNS injury and demyelinating diseases[1][3]
07

Biomarkers

Elevated Nogo-A expression may serve as a biomarker in neurodegenerative diseases and CNS injury contexts[4][6]

Beyond the preview

Go deeper on Reticulon-4 (Nogo-A) (Nogo-A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reticulon-4 (Nogo-A) (Nogo-A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call